more_reports

The Latest Biotechnology / Pharmaceuticals Articles from Streetwise Reports

Viking Therapeutics Expands Obesity Pipeline With VK3019 Phase 1

  ()
Viking Therapeutics launches Phase 1 trial for VK3019 amylin agonist. Discover how this dual-receptor candidate fits the company's expanding obesity strategy and upcoming catalysts for investors.
Tags: Biotechnology / Pharmaceuticals

uniQure Epilepsy Gene Therapy Data Draws Investor Focus

  ()
uniQure reports early AMT-260 results for refractory MTLE. See the trial data, pipeline catalysts, analyst price target, and what retail investors should watch next.
Tags: Biotechnology / Pharmaceuticals

A New Obesity Drug Just Reached Human Trials. Here's What Comes Next

  ()
Viking Therapeutics Inc. (VKTX:NASDAQ) initiated a Phase 1 clinical trial of its investigational weight-loss candidate VK3019, following FDA clearance of its IND application.
Tags: Biotechnology / Pharmaceuticals

San Diego Biopharma Begins First-in-Human Dosing of Obesity Drug as Phase 3 Catalysts Approach

Research Report
  ()
A San Diego clinical-stage biopharma dosed its first patient in a Phase 1 obesity study while advancing late-stage weight-loss programs toward key 20262027 readouts.
Tags: Biotechnology / Pharmaceuticals

Gene Therapy Co. Announces Initial Data for Refractory Epilepsy Treatment, Gets Buy Rating

  ()
uniQure N.V. (QURE:NASDAQ) announced initial six-month data for AMT-260 treating refractory epilepsy, with three of six patients showing 79-100% seizure reduction.
Tags: Biotechnology / Pharmaceuticals

Rezolute's Ersodetug Advances in Rare Hypoglycemia Treatment Amid Pharma Growth

  ()
Explore Rezolute Inc.'s progress with Ersodetug for hyperinsulinism, including ENDO 2026 data, analyst ratings, and sector trends for retail investors seeking biotech opportunities.
Tags: Biotechnology / Pharmaceuticals

Traws Pharma Positions Long-Acting Antivirals for Influenza and Outbreak Threats as Sector Opportunities Expand

  ()
Explore Traws Pharma's strategy in respiratory antivirals, cash runway to 2027, pipeline backups, and analyst perspectives amid evolving biopharma funding and flu market needs for retail investors.
Tags: Biotechnology / Pharmaceuticals

Biopharma Developer Unveils Breakthrough Hypoglycemia Treatment Data

  ()
Rezolute Inc. (RZLT:NASDAQ) presented promising data at ENDO 2026, with analysts eyeing big gains and a "Buy" rating as Phase 3 study results loom in the second half of 2026.
Tags: Biotechnology / Pharmaceuticals

Biopharma Co. Hits Regulatory Hurdle in High-Priority Bird Flu Program

  ()
Traws Pharma, Inc.'s (TRAW:NASDAQ) bird flu antiviral hits a U.K. regulatory hurdle, delaying its Phase 2a study and prompting an analyst downgrade from Buy to Neutral.
Tags: Biotechnology / Pharmaceuticals

enGene Therapeutics Positions Detalimogene for NMIBC Opportunity Amid Expanding Oncology Landscape

  ()
Explore how enGene Therapeutics is advancing its novel gene therapy, Detalimogene, for bladder cancer within a growing oncology market, including clinical progress, financial strength, and upcoming catalysts for investors.
Tags: Biotechnology / Pharmaceuticals

Teva Pharmaceutical Advances Neuroscience Pipeline With Strong AUSTEDO Growth and New Acquisition

  ()
Teva Pharmaceutical Industries reports robust first-quarter revenue growth from AUSTEDO and specialty products while closing the Emalex acquisition and advancing multiple late-stage programs in neuroscience, immunology, and respiratory diseases for retail investors.
Tags: Biotechnology / Pharmaceuticals

Oncology BioPharma Co. Reports Mixed Trial Data, Plots Path to FDA

  ()
enGene Therapeutics Inc. (ENGN:NASDAQ) shared Q2 results and LEGEND trial updates for detalimogene, its non-muscle invasive bladder cancer therapy, as analysts waver on stock.
Tags: Biotechnology / Pharmaceuticals

Nuvalent Acquisition by GSK Highlights Growing Opportunities in Targeted Oncology Therapies

  ()
Explore how the pending GSK acquisition of Nuvalent at a premium underscores sector momentum in precision oncology, with key pipeline catalysts and market trends for retail investors to consider.
Tags: Biotechnology / Pharmaceuticals

A New Pharma Giant Goes Public as a Sector Leader Makes Moves in Neuroscience

  ()
Apotex Health Corp. (APTX:TSX) raised approximately CA$1.3 billion in its IPO while Teva Pharmaceutical Industries Ltd. (TEVA:NYSE) reported new AUSTEDO data and added a late-stage Tourette syndrome asset.
Tags: Biotechnology / Pharmaceuticals

Analysts Cut Biopharma Co. to Neutral After Pending US$10.6B Deal

  ()
Analysts downgrade Nuvalent Inc (NUVL:NASDAQ) to "Neutral" after GSK's US$10.6B all-cash buyout offer at US$124/share, calling the deal favorable but a competing bid unlikely.
Tags: Biotechnology / Pharmaceuticals

Oculis Holding AG Pioneers Genotype-Based Precision Approach to Dry Eye Disease Treatment

  ()
Oculis Holding AG launches the PREDICT-1 trial for licaminlimab, targeting patients with a specific TNFR1 genotype to address unmet needs in the large dry eye disease market.
Tags: Biotechnology / Pharmaceuticals

Biopharma Co. Trials Precision Medicine Breakthrough for Dry Eye Disease. Gets Positive Results

  ()
Oculis Holding AG (OCS:NASDAQ; OCS:XICE) launches PREDICT-1, a genotype-based trial for licaminlimab, targeting 10M moderate-to-severe dry eye patients.
Tags: Biotechnology / Pharmaceuticals

MindBio Therapeutics Positions Voice AI Technology for Growth in Safety-Critical Sectors

  ()
Explore how MindBio Therapeutics is advancing voice-based AI detection for intoxication across mining, aviation, and other industries, backed by strong market trends and analyst targets.
Tags: Life Sciences Tools & DiagnosticsBiotechnology / Pharmaceuticals

ORIC Pharmaceuticals Positions for Growth in Expanding Oncology Market

  ()
Explore how ORIC Pharmaceuticals is advancing its oncology pipeline with key catalysts ahead, amid rising global demand for innovative cancer treatments and strong analyst support.
Tags: Biotechnology / Pharmaceuticals

Biotech Firm Deploys Revolutionary Intox AI, Unlocking Billion-Dollar Industrial Safety Opportunity

  ()
MindBio Therapeutics Corp. (MBIO:CSE; MBQIF:OTCQB; WF6:Frankfurt) launches Intox AI, detecting intoxication via voice, targeting mining and aviation in a US$2.06B market.
Tags: Life Sciences Tools & DiagnosticsBiotechnology / Pharmaceuticals

Clinical-Stage Biopharma Co. Issues New Inducement Stock Options for Growth

  ()
ORIC Pharmaceuticals Inc. (ORIC:NASDAQ) granted 34,800 stock options and 5,900 restricted stock units to new employees as analysts issue "Buy" ratings for the year ahead.
Tags: Biotechnology / Pharmaceuticals

Cancer Drug Developer Shifts 70% of Spending to Research as AI Pipeline Progresses

  ()
Rakovina Therapeutics (TSX.V: RKV) reported lower net losses, reduced administrative spending, debt restructuring, financing activity, and progress across its AI-driven oncology pipeline in Q1 2026.
Tags: Life Sciences Tools & DiagnosticsBiotechnology / Pharmaceuticals

California Pharma Co. Tests Breakthrough Cancer Drug, Cuts Death Risk 60%

  ()
Revolution Medicines Inc.'s (RVMD:NASDAQ) daraxonrasib treats pancreatic cancer patients, doubling median survival. Analysts rate it a "Buy" with targets up to US$263.
Tags: Biotechnology / Pharmaceuticals

US Biotech Co. Targets Muscular Dystrophy with First-In-Class Drug

  ()
Capricor Therapeutics Inc.'s (CAPR:NASDAQ) Deramiocel targets FDA approval by August 2026, with analysts issuing Buy ratings and price targets as high as US$60.
Tags: Biotechnology / Pharmaceuticals

Biopharma Company Reveals High-Impact SCI Recovery Gains

  ()
NervGen Pharma Corp. (NGEN:TSX.V; NGENF:OTCQX) reports 100% responder rates for NVG-291 in spinal cord injury trials, strengthening hopes for major recovery breakthroughs.
Tags: Biotechnology / Pharmaceuticals

Showing Results: 1 to 25 of 92 Next